Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
LONDON (AP) — British authorities and the country’s public health service knowingly exposed tens of2024-05-21Central government authorities support and welcome passage of Article 23 legislation in Hong Kong
Following the passing of the Article 23 legislation at the Legislative Council (LegCo) of the Hong K2024-05-21UK gov't considers ban on foreign states owning British news media
The United Kingdom's Prime Minister Rishi Sunak is contemplating the introduction of new measures em2024-05-21Deputies urged to help advance modernization
Developing whole-process people's democracy vital, top legislator saysStressing the importance of de2024-05-21- The 'real-life Martha' from Baby Reindeer bombarded Sir Keir Starmer with almost 300 emails, it has2024-05-21
China, Angola elevate bilateral ties
President Xi Jinping meets on Friday with Angolan President Joao Lourenco in Beijing. (Feng Yongbin2024-05-21
atest comment